Sacubitril And Valsartan Tablet, Film Coated
Product Images NDC 71610-955

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 71610-955). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (71610 0955 19)

Label (71610 0955 19)
This text contains information related to a medication called Sacubitril/Valsartan, with the NDC number 71610-955-19. The other text appears to be partially readable and indicates additional details about the medication.*
FDA Label Image

Aphena (Aphena)

Aphena (Aphena)
FDA Label Image

Figure-1 (Sacubitril Valsartan Figure 1)

Figure-1 (Sacubitril Valsartan Figure 1)
This text provides information on the geometric mean ratio and 90% confidence interval for the coadministered drugs listed, including Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HeTZ, Metformin, Atorvastatin, and Sildenafil. It also mentions a change relative to a reference.*
FDA Label Image

Figure-2 (Sacubitril Valsartan Figure 2)

Figure-2 (Sacubitril Valsartan Figure 2)
FDA Label Image

Sacubitril-valsartan-figure-3.jpg (Sacubitril Valsartan Figure 3)

Sacubitril-valsartan-figure-3.jpg (Sacubitril Valsartan Figure 3)
This text provides data from the PARADIGM-HF clinical trial comparing the effectiveness of Sacubitril and Valsartan combination therapy versus Enalapril in reducing cardiovascular death and heart failure hospitalizations. The figures show the time to first occurrence of cardiovascular death or heart failure hospitalizations, the time to occurrence of cardiovascular death, and the time to first occurrence of heart failure hospitalizations. Results indicate a significant difference favoring Sacubitril and Valsartan compared to Enalapril in reducing these events. The hazard ratios with 95% confidence intervals are provided for each comparison. Additional details include Kaplan-Meier estimates of cumulative failure rates over time.*
FDA Label Image

Structure (Sacubitril Valsartan Structure)

Structure (Sacubitril Valsartan Structure)
FDA Label Image

Sacubitril-valsartanl-figure-4.jpg (Sacubitril Valsartanl Figure 4)

Sacubitril-valsartanl-figure-4.jpg (Sacubitril Valsartanl Figure 4)
This text provides a breakdown of various demographic and health-related characteristics such as age, gender, weight, race, region, NYHA class, estimated GFR, diabetes, blood pressure, ejection fraction, atrial fibrillation, NT-proBNP, hypertension, prior medication use, hospitalization history, time since diagnosis, cause of heart failure, and usage of specific medications like Sacubitril, Valsartan, and Enalapril. Additionally, it includes numerical data on the percentage of subgroup populations within these categories. The text also mentions hazard ratios for Sacubitril and Valsartan as compared to Enalapril.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.